ORAFLOX INFUSION

Indications

• Bacterial infections
• Acute exacerbation of chronic obstructive pulmonary disease
• Community-acquired pneumonia
• Hospital-acquired pneumonia
• Urinary tract infections
• Complicated urinary tract infections
• Prostatitis
• Chronic pulmonary infections due to Pseudomonas aeruginosa
• Helicobacter pylori eradication (in combination with other drugs)

Dosage

Adults: 500 mg once daily for 5-14 days depending on the infection type and severity; for intravenous infusion, 500 mg to be given over at least 60 minutes.

Mechanism of action

Levofloxacin exerts its antimicrobial activity through the inhibition of two key bacterial enzymes: DNA gyrase and topoisomerase IV. DNA gyrase introduces negative supercoils into DNA during replication, while topoisomerase IV is essential for unlinking newly replicated chromosomes, allowing cell division. By inhibiting these enzymes, levofloxacin blocks DNA replication, resulting in cell death.

Pharmacodynamics

Levofloxacin is bactericidal and inhibits bacterial DNA replication. It has a longer duration of action than many other antibiotics, allowing for less frequent dosing. The drug may cause QTc-interval prolongation, necessitating caution in patients with risk factors for this condition. Levofloxacin shows in vitro activity against various bacterial pathogens, and while resistance can develop, it typically arises from mutations in target enzymes or drug efflux mechanisms.

Pharmacokinetics

Levofloxacin is well absorbed following oral administration, with peak plasma concentrations occurring within 1-2 hours. It has a volume of distribution of approximately 100 L and is approximately 30-40% protein bound. The drug is primarily excreted unchanged in the urine, with a half-life of about 6-8 hours, allowing for once or twice daily dosing.

Contra-indications

• Hypersensitivity to levofloxacin or other fluoroquinolones
• History of tendon disorders related to fluoroquinolone use
• Patients with a history of myasthenia gravis

Adverse effects

• Nausea
• Diarrhea
• Headache
• Dizziness
• QT interval prolongation
• Tendon rupture
• Clostridioides difficile-associated diarrhea
• Nephritis tubulointerstitial

Interactions

• Concurrent use with other drugs that prolong the QT interval
• Antacids, sucralfate, metal cations (e.g. magnesium, aluminum, calcium) can reduce absorption
• NSAIDs may increase the risk of CNS stimulation
• Warfarin may have increased anticoagulant effects

Precautions

• Use cautiously in patients with a history of seizures or CNS disorders
• Monitor for signs of tendon damage
• Consider risks in patients with electrolyte disturbances
• Use with caution in patients with renal impairment

Pregnancy

Manufacturer advises use only if potential benefit outweighs risk.

Breast-feeding

Manufacturer advises caution; levofloxacin may be excreted in breast milk.

Storage

Store at room temperature, away from moisture and heat. Protect from light.

Formulations

• 500 mg tablet for oral use
• Solution for intravenous infusion
• Nebuliser solution
• Eye drops

Indications

• Hypoglycemia
• Caloric supplementation in patients unable to eat
• Fluid replacement therapy
• Parenteral nutrition

Dosage

Children: Paediatric doses must be determined based on clinical condition and specific needs. Refer to the BNF for Children for appropriate dosing information.

Adults: The dosage of dextrose in adults varies based on clinical condition and route of administration. For hypoglycemia, intravenous dextrose 50% (D50W) is commonly administered. Refer to the BNF for specific dosing guidelines.

Mechanism of action

Dextrose supplies energy to tissues by generating ATP and NADH through glycolysis, where glucose is phosphorylated by hexokinase to form glucose 6-phosphate. This activates glucose for breakdown, ultimately converting glucose into energy molecules. Dextrose also plays a role in gene transcription, enzyme activity, and hormone secretion, regulating glucose homeostasis and cellular metabolic integrity.

Pharmacodynamics

Blood glucose acts as a crucial energy source for cellular activities and functions as a signaling molecule. It is oxidized into carbon dioxide and water, producing energy through glycolysis, the citric cycle, and oxidative phosphorylation. Dextrose can be converted into fat for energy storage and is stored as glycogen in the liver and muscles. Its administration, particularly orally, enhances insulin secretion due to stimulation of incretin hormones.

Pharmacokinetics

Dextrose is rapidly absorbed in the gastrointestinal tract, leading to a quick elevation of blood glucose levels. It is distributed throughout the body and can be utilized by various tissues for energy. The metabolism of dextrose primarily occurs in the liver, where it can be stored as glycogen or converted into fat. Renal excretion may occur when blood glucose levels are excessively high.

Adverse effects

• Hyperglycemia
• Fluid overload
• Hypokalemia
• Thrombophlebitis at injection site

Interactions

• Corticosteroids may increase blood glucose levels
• Beta-blockers may mask symptoms of hypoglycemia
• Diuretics may cause electrolyte imbalances

Precautions

• Use with caution in patients with diabetes mellitus
• Monitor blood glucose levels regularly
• Use cautiously in patients with renal impairment or heart failure

Pregnancy

Dextrose is generally considered safe for use during pregnancy when clinically indicated, but should be used with caution.

Breast-feeding

Dextrose can be used during breastfeeding as it is a natural sugar found in breast milk.

Storage

Store at room temperature, away from direct sunlight, and protect from freezing.

Formulations

• Dextrose 5% solution for infusion
• Dextrose 10% solution for infusion
• Dextrose 50% solution for injection
• Oral dextrose tablets

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations.

Adults: Refer to the BNF for specific dosing recommendations.

Mechanism of action

The exact mechanism of action for Hemi is not explicitly detailed in the available resources, but compounds with similar structure may act by modulating neurotransmitter levels, inhibiting enzymes, or affecting cellular signaling pathways.

Pharmacodynamics

Hemi may exhibit pharmacodynamic properties that include modulation of neural activity or inhibition of specific biochemical pathways. Its effects could be dose-dependent and vary based on the therapeutic context.

Pharmacokinetics

The pharmacokinetic profile of Hemi, including absorption, distribution, metabolism, and excretion, is not well-documented in the provided resources. Generally, compounds in this class may undergo first-pass metabolism and have a variable half-life.

Dosage

Children: Refer to the specific formulation or active ingredient for dosing information.

Adults: Refer to the specific formulation or active ingredient for dosing information.

Mechanism of action

The mechanism of action of hemihydrate forms of drugs can vary widely depending on the specific compound. In many cases, the hemihydrate form enhances the solubility of the active ingredient, which facilitates its dissolution and absorption in the gastrointestinal tract.

Pharmacodynamics

Pharmacodynamics of hemihydrate compounds generally relates to the pharmacological effects that arise from the active drug once it is absorbed. The effects may vary based on the specific drug and its therapeutic target, but overall, the hemihydrate form aims to improve efficacy by ensuring adequate plasma concentrations are achieved more effectively than non-hydrated forms.

Pharmacokinetics

The pharmacokinetics of hemihydrate drugs typically demonstrate improved dissolution rates due to the presence of water, which can lead to increased absorption. This may result in quicker onset of action and modified half-lives. The specifics of absorption, distribution, metabolism, and excretion will depend on the active ingredient and its properties.

Pregnancy

Safety in pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether this drug is excreted in human milk. Caution should be exercised when administered to a nursing mother.

Storage

Store at room temperature, away from moisture and heat. Keep container tightly closed.

Mechanism of action

Levofloxacin, like other fluoroquinolone antibiotics, exerts its antimicrobial activity via the inhibition of two key bacterial enzymes: DNA gyrase and topoisomerase IV. Both targets are type II topoisomerases, but have unique functions within the bacterial cell. DNA gyrase is an enzyme found only in bacteria that introduces negative supercoils into DNA during replication - this helps to relieve torsional strain caused by the introduction of positive supercoils during replication, and these negative supercoils are essential for chromosome condensation and the promotion of transcription initiation. It is comprised of four subunits (two A subunits and two B subunits) of which the A subunits appear to be the target of fluoroquinolone antibiotics. Bacterial topoisomerase IV, in addition to contributing to the relaxation of positive supercoils, is essential at the terminal stages of DNA replication and functions to “unlink” newly replicated chromosomes to allow for the completion of cell division. Inhibition of these enzymes by levofloxacin likely occurs via complexation with the topoisomerase enzymes. The end result is a blockade of DNA replication, thus inhibiting cell division and resulting in cell death. Levofloxacin is the L-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. The antibacterial activity of ofloxacin resides primarily in the L-isomer. The mechanism of action of levofloxacin and other fluoroquinolone antimicrobials involves inhibition of bacterial topoisomerase IV and DNA gyrase (both of which are type II topoisomerases), enzymes required for DNA replication, transcription, repair and recombination. Fluoroquinolones prolong the QT interval by blocking voltage-gated potassium channels, especially the rapid component of the delayed rectifier potassium current I(Kr), expressed by HERG (the human ether-a-go-go-related gene). According to the available case reports and clinical studies, moxifloxacin carries the greatest risk of QT prolongation from all available quinolones in clinical practice and it should be used with caution in patients with predisposing factors for Torsades de pointes (TdP).

Pharmacodynamics

Levofloxacin is bactericidal and exerts its antimicrobial effects via inhibition of bacterial DNA replication. It has a relatively long duration of action in comparison with other antibiotics that allows for once or twice daily dosing. Levofloxacin is associated with QTc-interval prolongation and should be used with caution in patients with other risk factors for prolongation (e.g. hypokalemia, concomitant medications). Levofloxacin has demonstrated _in vitro_ activity against a number of aerobic gram-positive and gram-negative bacteria and may carry some activity against certain species of anaerobic bacteria and other pathogens such as _Chlamydia_ and _Legionella_. Resistance to levofloxacin may develop, and is generally due to mutations in DNA gyrase or topoisomerase IV, or via alterations to drug efflux. Cross-resistance may occur between levofloxacin and other fluoroquinolones, but is unlikely to develop between levofloxacin and other antibiotic classes (e.g. macrolides) due to significant differences in chemical structure and mechanism of action. As antimicrobial susceptibility patterns are geographically distinct, local antibiograms should be consulted to ensure adequate coverage of relevant pathogens prior to use.

Mechanism of action

Glucose supplies most of the energy to all tissues by generating energy molecules ATP and NADH during a series of metabolism reactions called glycolysis. Glycolysis can be divided into two main phases where the preparatory phase is initiated by the phosphorylation of glucose by hexokinase to form glucose 6-phosphate. The addition of the high-energy phosphate group activates glucose for the subsequent breakdown in later steps of glycolysis and is the rate-limiting step. Products end up as substrates for following reactions, to ultimately convert C6 glucose molecule into two C3 sugar molecules. These products enter the energy-releasing phase where the total of 4ATP and 2NADH molecules are generated per one glucose molecule. The total aerobic metabolism of glucose can produce up to 36 ATP molecules. These energy-producing reactions of glucose are limited to D-glucose as L-glucose cannot be phosphorylated by hexokinase. Glucose can act as precursors to generate other biomolecules such as vitamin C. It plays a role as a signaling molecule to control glucose and energy homeostasis. Glucose can regulate gene transcription, enzyme activity, hormone secretion, and the activity of glucoregulatory neurons. The types, number, and kinetics of glucose transporters expressed depends on the tissues and fine-tunes glucose uptake, metabolism, and signal generation to preserve cellular and whole body metabolic integrity. Vascular calcification is a hallmark of type 2 diabetes. Glucose stimulates calcification in culture of vascular smooth muscle cells (VSMCs) but the underlying mechanisms remain obscure. We observed that high glucose levels stimulated mouse and human VSMC trans-differentiation into chondrocytes, with increased levels of Sox9, type II collagen, glycosaminoglycan and Runx2 expression, and increased alkaline phosphatase activity and mineralization. These effects were associated with increased expression of IL-1beta, which stimulated alkaline phosphatase and calcification, suggesting that glucose induces chondrocyte differentiation of VSMCs, possibly through IL-1beta activation.

Pharmacodynamics

Blood glucose is an obligatory energy source for humans involved in various cellular activities, and it also acts as a signaling molecule for diverse glucose-sensing molecules and proteins. Glucose undergoes oxidation into carbon dioxide, water, and yields energy molecules in the process of glycolysis and subsequent citric cycle and oxidative phosphorylation. Glucose is readily converted into fat in the body which can be used as a source of energy as required. Under a similar conversion into storage of energy, glucose is stored in the liver and muscles as glycogen. Glucose stores are mobilized in a regulated manner, depending on the tissues' metabolic demands. Oral glucose tablets or injections serve to increase the supply of glucose and oral glucose administration is more effective in stimulating insulin secretion because it stimulates the incretin hormones from the gut, which promotes insulin secretion.